NOVARTIS Australia's Scemblix (asciminib) is now listed on the PBS for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKI).
Novartis also welcomes the listing of Scemblix for the treatment of Ph CML in CP with the T315I mutation.
Scemblix is a novel treatment option that works by specifically targeting the ABL myristoyl pocket (also known as a STAMP inhibitor in scientific literature), offering a reimagined treatment approach for patients, who experience intolerance and/or resistance to currently available TKI therapies.
The approval is based on results from the pivotal Phase III ASCEMBL trial.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 May 23
